{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T06:40:35Z","timestamp":1790404835564,"version":"4.1.0"},"reference-count":38,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100004948","name":"Astellas Pharma Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004948","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmacology"],"published-print":{"date-parts":[[2021,6]]},"DOI":"10.1016\/j.ejphar.2021.174076","type":"journal-article","created":{"date-parts":[[2021,3,31]],"date-time":"2021-03-31T07:30:07Z","timestamp":1617175807000},"page":"174076","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"special_numbering":"C","title":["Effects of SGLT2 inhibitor ipragliflozin alone and combined with pioglitazone on fluid retention in type 2 diabetic mice with NASH"],"prefix":"10.1016","volume":"901","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6963-0882","authenticated-orcid":false,"given":"Atsuo","family":"Tahara","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejphar.2021.174076_bib1","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1016\/j.metabol.2016.04.004","article-title":"Pharmacological management of nonalcoholic fatty liver disease","volume":"65","author":"Barb","year":"2016","journal-title":"Metabolism"},{"key":"10.1016\/j.ejphar.2021.174076_bib2","doi-asserted-by":"crossref","first-page":"628628","DOI":"10.1155\/2013\/628628","article-title":"Thiazolidinedione-induced fluid retention: recent insights into the molecular mechanisms","volume":"2013","author":"Be\u0142towski","year":"2013","journal-title":"PPAR Res.."},{"key":"10.1016\/j.ejphar.2021.174076_bib3","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1681\/ASN.2008020225","article-title":"Mechanisms of ENaC regulation and clinical implications","volume":"19","author":"Bhalla","year":"2008","journal-title":"J. Am. Soc. Nephrol."},{"key":"10.1016\/j.ejphar.2021.174076_bib4","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1111\/j.1365-2036.2011.04912.x","article-title":"Meta-analysis: pioglitazone improves liver histology and fibrosis in patients with non-alcoholic steatohepatitis","volume":"35","author":"Boettcher","year":"2012","journal-title":"Aliment. Pharmacol. Ther."},{"key":"10.1016\/j.ejphar.2021.174076_bib5","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1016\/j.cgh.2017.12.001","article-title":"Response to pioglitazone in patients with nonalcoholic steatohepatitis with vs without type 2 diabetes","volume":"16","author":"Bril","year":"2018","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"10.1016\/j.ejphar.2021.174076_bib6","doi-asserted-by":"crossref","first-page":"4","DOI":"10.2337\/diaclin.32.1.4","article-title":"SGLT-2 inhibitors: a new mechanism for glycemic control","volume":"32","author":"Chao","year":"2014","journal-title":"Clin. Diabetes"},{"key":"10.1016\/j.ejphar.2021.174076_bib7","doi-asserted-by":"crossref","first-page":"297","DOI":"10.2147\/VHRM.S993","article-title":"Peroxisome proliferator-activated receptor-gamma agonists and diabetes: current evidence and future perspectives","volume":"4","author":"Chiarelli","year":"2008","journal-title":"Vasc. Health Risk Manag."},{"key":"10.1016\/j.ejphar.2021.174076_bib8","article-title":"Effects of sodium-glucose co-transporter 2 inhibitors on liver parameters and steatosis: a meta-analysis of randomized clinical trials","author":"Coelho","year":"2020","journal-title":"Diabetes Metab. Res. Rev."},{"key":"10.1016\/j.ejphar.2021.174076_bib9","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1038\/nm1278","article-title":"Thiazolidinediones expand body fluid volume through PPARgamma stimulation of ENaC-mediated renal salt absorption","volume":"11","author":"Guan","year":"2005","journal-title":"Nat. Med."},{"key":"10.1016\/j.ejphar.2021.174076_bib10","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0146337","article-title":"The selective SGLT2 inhibitor ipragliflozin has a therapeutic effect on nonalcoholic steatohepatitis in mice","volume":"11","author":"Honda","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.ejphar.2021.174076_bib11","doi-asserted-by":"crossref","first-page":"646423","DOI":"10.1155\/2015\/646423","article-title":"Thiazolidinediones and edema: recent advances in the pathogenesis of thiazolidinediones-induced renal sodium retention","volume":"2015","author":"Horita","year":"2015","journal-title":"PPAR Res.."},{"key":"10.1016\/j.ejphar.2021.174076_bib12","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.2337\/dc17-0518","article-title":"Comparison of ipragliflozin and pioglitazone effects on nonalcoholic fatty liver disease in patients with type 2 diabetes: a randomized, 24-week, open-label, active-controlled trial","volume":"40","author":"Ito","year":"2017","journal-title":"Diabetes Care"},{"key":"10.1016\/j.ejphar.2021.174076_bib13","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.pharmthera.2013.04.003","article-title":"Ipragliflozin and other sodium-glucose cotransporter-2 (SGLT2) inhibitors in the treatment of type 2 diabetes: preclinical and clinical data","volume":"139","author":"Kurosaki","year":"2013","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.ejphar.2021.174076_bib14","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1016\/j.metabol.2005.04.015","article-title":"The effects of thiazolidinedione treatment on the regulations of aquaglyceroporins and glycerol kinase in OLETF rats","volume":"54","author":"Lee","year":"2005","journal-title":"Metabolism"},{"key":"10.1016\/j.ejphar.2021.174076_bib15","doi-asserted-by":"crossref","first-page":"57","DOI":"10.3892\/br.2012.18","article-title":"Metformin in non-alcoholic fatty liver disease: a systematic review and meta-analysis","volume":"1","author":"Li","year":"2013","journal-title":"Biomed Rep."},{"key":"10.1016\/j.ejphar.2021.174076_bib16","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1053\/jhep.2003.50161","article-title":"Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome","volume":"37","author":"Marchesini","year":"2003","journal-title":"Hepatology"},{"key":"10.1016\/j.ejphar.2021.174076_bib17","first-page":"450639","article-title":"Nonalcoholic Fatty liver disease, diabetes mellitus and cardiovascular disease: newer data","volume":"2013","author":"Mavrogiannaki","year":"2013","journal-title":"Internet J. Endocrinol."},{"key":"10.1016\/j.ejphar.2021.174076_bib18","first-page":"S17","article-title":"Pathophysiology of nonalcoholic steatohepatitis","volume":"40","author":"McCullough","year":"2006","journal-title":"J. Clin. Gastroenterol."},{"key":"10.1016\/j.ejphar.2021.174076_bib19","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1515\/med-2018-0059","article-title":"Ipragliflozin ameliorates liver damage in non-alcoholic fatty liver disease","volume":"13","author":"Miyake","year":"2018","journal-title":"Open Med."},{"key":"10.1016\/j.ejphar.2021.174076_bib20","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1507\/endocrj.EJ18-0022","article-title":"Efficacy and safety of sodium-glucose cotransporter 2 inhibitor ipragliflozin on glycemic control and cardiovascular parameters in Japanese patients with type 2 diabetes mellitus; Fukuoka Study of Ipragliflozin (FUSION)","volume":"65","author":"Nomiyama","year":"2018","journal-title":"Endocr. J."},{"key":"10.1016\/j.ejphar.2021.174076_bib21","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1080\/14656566.2017.1363888","article-title":"Ipragliflozin, a sodium glucose co-transporter 2 inhibitor, reduces intrahepatic lipid content and abdominal visceral fat volume in patients with type 2 diabetes","volume":"18","author":"Ohta","year":"2017","journal-title":"Expet Opin. Pharmacother."},{"key":"10.1016\/j.ejphar.2021.174076_bib22","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/s40842-016-0027-7","article-title":"Treatment of nonalcoholic fatty liver disease (NAFLD) in patients with type 2 diabetes mellitus","volume":"2","author":"Portillo-Sanchez","year":"2016","journal-title":"Clin. Diabetes Endocrinol."},{"key":"10.1016\/j.ejphar.2021.174076_bib23","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.diabet.2019.01.008","article-title":"Beneficial effects of SGLT2 inhibitors on fatty liver in type 2 diabetes: a common comorbidity associated with severe complications","volume":"45","author":"Scheen","year":"2019","journal-title":"Diabetes Metab."},{"key":"10.1016\/j.ejphar.2021.174076_bib24","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1124\/jpet.103.058008","article-title":"Rosiglitazone activates renal sodium- and water-reabsorptive pathways and lowers blood pressure in normal rats","volume":"308","author":"Song","year":"2004","journal-title":"J. Pharmacol. Exp. Therapeut."},{"key":"10.1016\/j.ejphar.2021.174076_bib25","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/j.ejphar.2013.05.014","article-title":"Effects of SGLT2 selective inhibitor ipragliflozin on hyperglycemia, hyperlipidemia, hepatic steatosis, oxidative stress, inflammation, and obesity in type 2 diabetic mice","volume":"715","author":"Tahara","year":"2013","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.ejphar.2021.174076_bib26","article-title":"SGLT2 inhibitor ipragliflozin alone and combined with pioglitazone prevents progression of nonalcoholic steatohepatitis in a type 2 diabetes rodent model","volume":"7","author":"Tahara","year":"2019","journal-title":"Phys. Rep."},{"key":"10.1016\/j.ejphar.2021.174076_bib27","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.ejphar.2017.05.019","article-title":"Characterization and comparison of SGLT2 inhibitors: Part 3. Effects on diabetic complications in type 2 diabetic mice","volume":"809","author":"Tahara","year":"2017","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.ejphar.2021.174076_bib28","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1507\/endocrj.EJ16-0295","article-title":"Amelioration of fatty liver index in patients with type 2 diabetes on ipragliflozin: an association with glucose-lowering effects","volume":"64","author":"Takase","year":"2017","journal-title":"Endocr. J."},{"key":"10.1016\/j.ejphar.2021.174076_bib29","doi-asserted-by":"crossref","first-page":"2739","DOI":"10.2169\/internalmedicine.8754-16","article-title":"The improvement of the hepatic histological findings in a patient with non-alcoholic steatohepatitis with type 2 diabetes after the administration of the sodium-glucose cotransporter 2 inhibitor ipragliflozin","volume":"56","author":"Takeda","year":"2017","journal-title":"Intern. Med."},{"key":"10.1016\/j.ejphar.2021.174076_bib30","first-page":"649","article-title":"Nonalcoholic steatohepatitis (NASH) and hepatic fibrosis: emerging therapies","volume":"vol. 58","author":"Wattacheril","year":"2018"},{"key":"10.1016\/j.ejphar.2021.174076_bib31","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1038\/gt.2010.41","article-title":"PPARgamma is essential for protection against nonalcoholic steatohepatitis","volume":"17","author":"Wu","year":"2010","journal-title":"Gene Ther."},{"key":"10.1016\/j.ejphar.2021.174076_bib32","doi-asserted-by":"crossref","first-page":"8130968","DOI":"10.1155\/2017\/8130968","article-title":"Fluid retention caused by rosiglitazone is related to increases in AQP2 and \u03b1ENaC membrane expression","volume":"2017","author":"Xu","year":"2017","journal-title":"PPAR Res."},{"key":"10.1016\/j.ejphar.2021.174076_bib33","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1507\/endocrj.EJ19-0136","article-title":"Factors with remission of fatty liver in patients with type 2 diabetes treated with ipragliflozin","volume":"66","author":"Yamauchi","year":"2019","journal-title":"Endocr. J."},{"key":"10.1016\/j.ejphar.2021.174076_bib34","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1097\/MNH.0b013e32834de526","article-title":"PPAR\u03b3 as a therapeutic target in diabetic nephropathy and other renal diseases","volume":"21","author":"Yang","year":"2012","journal-title":"Curr. Opin. Nephrol. Hypertens."},{"key":"10.1016\/j.ejphar.2021.174076_bib35","doi-asserted-by":"crossref","first-page":"943614","DOI":"10.1155\/2008\/943614","article-title":"Renal and vascular mechanisms of thiazolidinedione-induced fluid retention","volume":"2008","author":"Yang","year":"2008","journal-title":"PPAR Res."},{"key":"10.1016\/j.ejphar.2021.174076_bib36","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.ejphar.2014.01.040","article-title":"SGLT2 selective inhibitor ipragliflozin reduces body fat mass by increasing fatty acid oxidation in high-fat diet-induced obese rats","volume":"727","author":"Yokono","year":"2014","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.ejphar.2021.174076_bib37","doi-asserted-by":"crossref","first-page":"9406","DOI":"10.1073\/pnas.0501744102","article-title":"Collecting duct-specific deletion of peroxisome proliferator-activated receptor gamma blocks thiazolidinedione-induced fluid retention","volume":"102","author":"Zhang","year":"2005","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.ejphar.2021.174076_bib38","doi-asserted-by":"crossref","first-page":"F1491","DOI":"10.1152\/ajprenal.00004.2013","article-title":"Increased susceptibility of db\/db mice to rosiglitazone-induced plasma volume expansion: role of dysregulation of renal water transporters","volume":"305","author":"Zhou","year":"2013","journal-title":"Am. J. Physiol. Ren. Physiol."}],"container-title":["European Journal of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299921002296?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299921002296?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,15]],"date-time":"2025-09-15T22:47:40Z","timestamp":1757976460000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0014299921002296"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6]]},"references-count":38,"alternative-id":["S0014299921002296"],"URL":"https:\/\/doi.org\/10.1016\/j.ejphar.2021.174076","relation":{},"ISSN":["0014-2999"],"issn-type":[{"value":"0014-2999","type":"print"}],"subject":[],"published":{"date-parts":[[2021,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effects of SGLT2 inhibitor ipragliflozin alone and combined with pioglitazone on fluid retention in type 2 diabetic mice with NASH","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejphar.2021.174076","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"174076"}}